Peak Bio, Inc. (PKBO)
OTCMKTS: PKBO · Delayed Price · USD
0.0085
+0.0033 (63.46%)
Apr 24, 2024, 10:55 AM EDT - Market open
Company Description
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases.
The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome.
It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.
Peak Bio, Inc.
| Country | Canada |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Dr. Stephen LaMond M.B.A., Pharm.D., PharmD MBA |
Contact Details
Address: 4900 Hopyard Road, Suite 100 Pleasanton, California 94588 United States | |
| Phone | (925) 463-4800 |
| Website | peak-bio.com |
Stock Details
| Ticker Symbol | PKBO |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001834645 |
| ISIN Number | US70470P1084 |
| Employer ID | 85-2448157 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hoyoung Huh M.D., Ph.D. | Executive Chairman (Leave of Absence) |
| Dr. Stephen LaMond M.B.A., Pharm.D., PharmD MBA | Interim Chief Executive Officer, Chief Operating Officer, Secretary and Director |
| Dr. Satyajit Mitra Ph.D. | Head of Oncology and Executive Director |
| Timothy M. Cunningham CPA, M.B.A. | Acting Chief Financial Officer |
| Moddy Wong | Director of Human Resources |
| Divya Patel | Controller and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 5, 2024 | 425 | Filing |
| Mar 5, 2024 | 425 | Filing |
| Mar 5, 2024 | 8-K | Current Report |
| Feb 21, 2024 | 8-K | Current Report |
| Feb 6, 2024 | 8-K | Current Report |
| Jan 29, 2024 | 8-K | Current Report |
| Jan 3, 2024 | 8-K | Current Report |
| Dec 22, 2023 | 8-K | Current Report |
| Nov 16, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |